Peregrine Pharmaceuticals (PPHM +15%) continue to rise ahead of its September 7 presentation at...

|About: Peregrine Pharmaceuticals Inc. (PPHM)|By:, SA News Editor

Peregrine Pharmaceuticals (PPHM +15%) continue to rise ahead of its September 7 presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, where the drug developer will present Phase II trial data for bavituximab, its drug candidate to treat non-small cell lung cancer.